Pittsburgh Seeks Breast Cancer Patients for Study on Coping

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

PITTSBURGH--The University of Pittsburgh Cancer Institute’s Division of Behavioral Medicine and Oncology is seeking young women with breast cancer for a research study on helping families cope with cancer.

PITTSBURGH--The University of Pittsburgh Cancer Institute’s Division of Behavioral Medicine and Oncology is seeking young women with breast cancer for a research study on helping families cope with cancer.

The women will participate in educational and support groups for couples to discuss coping with a chronic illness, stress management skills, family communication, and parenting concerns. These groups, led by an oncology nurse and a health psychologist, will meet 1½ hours once a week for 8 weeks.

In addition, groups for children ages 3 to 12 may be available and would take place at the same time as the parent groups. The children will receive support and develop their skills for coping with feelings and managing stress.

To be eligible for this study, women must be premenopausal and have been diagnosed with breast cancer in the past 5 years, have a partner, and have children between the ages of 3 and 12. For more information, call 412-624-4806.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content